For the best experience on the Abcam website please upgrade to a modern browser such as Google Chrome
|Sample type||Average %||Range|
|Cell culture supernatant||98||97% - 99%|
|Urine||92||90% - 94%|
|Serum||97||94% - 101%|
|Heparin Plasma||91||91% - %|
|EDTA Plasma||94||90% - 97%|
|Citrate Plasma||92||91% - 95%|
Human MCP1 SimpleStep ELISA® (ab179886) has been re-developed with new capture and detector antibodies. We have identified new recombinant monoclonal antibodies to use in the SimpleStep ELISA platform that provide a higher sensitivity when quantifying MCP1 in human serum, plasma, urine and cell culture supernatants.
MCP1 in vitro SimpleStep ELISA (Enzyme-Linked Immunosorbent Assay) kit is designed for the quantitative measurement of MCP1 protein in human serum, plasma, urine, and cell culture supernatant samples.
The SimpleStep ELISA employs an affinity tag labeled capture antibody and a reporter conjugated detector antibody which immunocapture the sample analyte in solution. This entire complex (capture antibody/analyte/detector antibody) is in turn immobilized via immunoaffinity of an anti-tag antibody coating the well. To perform the assay, samples or standards are added to the wells, followed by the antibody mix. After incubation, the wells are washed to remove unbound material. TMB substrate is added and during incubation is catalyzed by HRP, generating blue coloration. This reaction is then stopped by addition of Stop Solution completing any color change from blue to yellow. Signal is generated proportionally to the amount of bound analyte and the intensity is measured at 450 nm. Optionally, instead of the endpoint reading, development of TMB can be recorded kinetically at 600 nm.
MCP1 (CCL2) is a chemotactic factor that attracts monocytes and basophils but not neutrophils or eosinophils. Augments monocyte anti-tumor activity. Has been implicated in the pathogenesis of diseases characterized by monocytic infiltrates, like psoriasis, rheumatoid arthritis or atherosclerosis. May be involved in the recruitment of monocytes into the arterial wall during the disease process of atherosclerosis.
|Components||1 x 96 tests|
|10X Human MCP1 Capture Antibody||1 x 600µl|
|10X Human MCP1 Detector Antibody||1 x 600µl|
|10X Wash Buffer PT (ab206977)||1 x 20ml|
|Antibody Diluent CPI||1 x 6ml|
|Human MCP1 Lyophilized Recombinant Protein||2 vials|
|Plate Seals||1 unit|
|Sample Diluent NS||1 x 50ml|
|SimpleStep Pre-Coated 96-Well Microplate (ab206978)||1 unit|
|Stop Solution||1 x 12ml|
|TMB Development Solution||1 x 12ml|
Our Abpromise guarantee covers the use of ab179886 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
|Sandwich ELISA||Use at an assay dependent concentration.|
The MCP1 standard curve was prepared as described in Section 10. Raw data values are shown in the table. Background-subtracted data values (mean +/- SD) are graphed.
The concentrations of MCP1 were measured in duplicates, interpolated from the MCP1 standard curves and corrected for sample dilution. Undiluted samples are as follows: serum 100%, plasma (citrate) 25%, plasma (heparin), 25%, plasma (EDTA), urine 100%, and PHA stimulated PBMC supernatant 0.25%. The interpolated dilution factor corrected values are plotted (mean +/- SD, n=2). The mean MCP1 concentration was determined to be 72 pg/mL in serum, 96 pg/mL in plasma (citrate), 101 pg/mL in plasma (heparin), 88 pg/mL plasma (EDTA), 144 pg/mL in urine, and 70217 pg/mL in PHA stimulated PBMC supernatant.
Interpolated dilution factor corrected values are plotted (mean +/- SD, n=2). The mean MCP1 concentration was determined to be 113 pg/mL with a range of 58 - 247 pg/mL.
Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"